New marburg vaccine trial launches: could it stop the deadly virus?
NCT ID NCT07425821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new vaccine (rVSVΔG-MARV-GP) to see if it is safe and triggers an immune response against Marburg virus, a rare but severe disease. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo. The study focuses on side effects and antibody levels over several months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
George Washington University
RECRUITINGWashington D.C., District of Columbia, 20052, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johnson County Clin-Trials
RECRUITINGLenexa, Kansas, 66219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.